Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicenter, Phase III Study

Soon Jun Hong; Han Saem Jeong; Seung Hwan Han; Ki Yuk Chang; Bum Kee Hong; Bong Ki Lee; Shung Chull Chae; Woo Shik Kim; Chang Gyu Park; Jung Ho Heo; Seung Uk Lee; Young Dae Kim; Kee Sik Kim; Jung Hyun Choi; Hyun Jae Kang; Jae Joong Kim; Seok Min Kang; Young Jin Choi; Joon Han Shin; Kook Jin Chun; Dong Gu Shin; Seong Hoon Park; Jun Kwan; Yu Jeong Choi; Myung Ho Jeong; Jei Keon Chae; Dong Woon Kim; Jung Rae Cho; Kyoo Rok Han; Kyung Heon Won; Sang Ho Park; Sang Kon Lee; Sang Hoon Kim; Jina Jung; Cheol Ho Kim

doi:10.1016/j.clinthera.2017.08.013

Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicenter, Phase III Study

Clinical Therapeutics ◽

10.1016/j.clinthera.2017.08.013 ◽

2017 ◽

Vol 39 (10) ◽

pp. 2049-2060 ◽

Cited By ~ 2

Author(s):

Soon Jun Hong ◽

Han Saem Jeong ◽

Seung Hwan Han ◽

Ki Yuk Chang ◽

Bum Kee Hong ◽

...

Keyword(s):

Phase Iii ◽

Losartan Potassium ◽

Fixed Dose ◽

Double Blind ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study

Clinical Therapeutics ◽

10.1016/j.clinthera.2016.09.005 ◽

2016 ◽

Vol 38 (10) ◽

pp. 2171-2184 ◽

Cited By ~ 13

Author(s):

Sang-Hyun Kim ◽

Sang-Ho Jo ◽

Sang-Cheol Lee ◽

Sung-Yoon Lee ◽

Myung-Ho Yoon ◽

...

Keyword(s):

Blood Pressure ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Double Blind ◽

Cholesterol Lowering ◽

Multicenter Phase ◽

Phase Iii Study ◽

Dose Combination

Download Full-text

Effects of Fixed-Dose Combination of Low-Intensity Rosuvastatin and Ezetimibe Versus Moderate-Intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-Blind, Multicenter, Phase III Study

Clinical Therapeutics ◽

10.1016/j.clinthera.2021.07.016 ◽

2021 ◽

Author(s):

Seung-Ah Lee ◽

Weon Kim ◽

Taek Jong Hong ◽

Youngkeun Ahn ◽

Moo Hyun Kim ◽

...

Keyword(s):

Lipid Profiles ◽

Fixed Dose Combination ◽

Phase Iii ◽

Moderate Intensity ◽

Fixed Dose ◽

Double Blind ◽

Low Intensity ◽

Multicenter Phase ◽

Phase Iii Study ◽

Dose Combination

Download Full-text

Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 fatty acids 4 g Fixed-Dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients Who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Study

Clinical Therapeutics ◽

10.1016/j.clinthera.2021.07.001 ◽

2021 ◽

Author(s):

Jong Shin Woo ◽

Soon Jun Hong ◽

Dong Hoon Cha ◽

Kee Sik Kim ◽

Moo Hyun Kim ◽

...

Keyword(s):

Fatty Acids ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study ◽

Dose Combination

Download Full-text

Sa1217 Once Daily Dosing of 9mg Budesonide (Budenofalk®) Is Therapeutic Equivalent to a Three-Times Daily Dosing of 3mg Budesonide for the Treatment of Active Crohn's Disease: A Randomized, Double-Blind, Double-Dummy, Multicenter Phase III Study

Gastroenterology ◽

10.1016/s0016-5085(13)60823-9 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-233 ◽

Cited By ~ 1

Author(s):

Axel U. Dignass ◽

Simeon Stoynov ◽

Andrey E. Dorofeyev ◽

Galina A. Grigorieva ◽

Eva Tomsova ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Phase Iii ◽

Double Blind ◽

Once Daily ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

Pituitary ◽

10.1007/s11102-014-0585-6 ◽

2014 ◽

Vol 18 (3) ◽

pp. 385-394 ◽

Cited By ~ 40

Author(s):

Michael Sheppard ◽

Marcello D. Bronstein ◽

Pamela Freda ◽

Omar Serri ◽

Laura De Marinis ◽

...

Keyword(s):

Phase Iii ◽

Extension Phase ◽

Double Blind ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III study

Endocrine Abstracts ◽

10.1530/endoabs.32.p847 ◽

2013 ◽

Cited By ~ 3

Author(s):

Pamela Freda ◽

Maria Fleseriu ◽

der Lely Aart Jan van ◽

Annamaria Colao ◽

Michael Sheppard ◽

...

Keyword(s):

Phase Iii ◽

Biochemical Control ◽

Double Blind ◽

Octreotide Lar ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study

Endocrine Abstracts ◽

10.1530/endoabs.32.p845 ◽

2013 ◽

Author(s):

Michael Sheppard ◽

Marcello Bronstein ◽

Pamela Freda ◽

Omar Serri ◽

Marinis Laura De ◽

...

Keyword(s):

Phase Iii ◽

Extension Phase ◽

Double Blind ◽

Octreotide Lar ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps152 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS152-TPS152 ◽

Cited By ~ 6

Author(s):

P. E. Goss ◽

C. H. Barrios ◽

R. Bell ◽

D. Finkelstein ◽

H. Iwata ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Stage ◽

Disease Recurrence ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Multicenter Phase ◽

Phase Iii Study ◽

Risk Of Disease

Download Full-text

Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status

Annals of Oncology ◽

10.1093/annonc/mdv340.05 ◽

2015 ◽

Vol 26 ◽

pp. vi37 ◽

Cited By ~ 2

Author(s):

A. Sobrero ◽

L. Latini ◽

C. Barone ◽

F. Capuzzo ◽

M. Banzi ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Combination Therapy ◽

Subgroup Analysis ◽

Phase Iii ◽

Metastatic Colorectal Carcinoma ◽

First Line ◽

Double Blind ◽

Multicenter Phase ◽

Kras Status ◽

Phase Iii Study

Download Full-text

A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdg019 ◽

2003 ◽

Vol 14 (1) ◽

pp. 29-35 ◽

Cited By ~ 399

Author(s):

M.D. Green ◽

H. Koelbl ◽

J. Baselga ◽

A. Galid ◽

V. Guillem ◽

...

Keyword(s):

Phase Iii ◽

Single Administration ◽

Double Blind ◽

Myelosuppressive Chemotherapy ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text